Ahmed Shoyb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ahmed Shoyb has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Bassiony
Department of Neuropsychiatry, Faculty of Medicine, Ain Shams University, Cairo
2 shared publicationsBastawy Fawal
Department of Neuropsychiatry, Faculty of Medicine, Aswan University, Aswan, Egypt
2 shared publications- Eman Mohamed Khedr
Assiut University
2 shared publications Hany Zaky-Eldin
Department of Neuropsychiatry, Faculty of Medicine, Ain Shams University, Cairo
2 shared publications- Abeer Abdelhady Tony
Department of Neuropsychiatry, Faculty of Medicine, Aswan University, Aswan, Egypt
1 shared publication - Amany Mansour Mohamed
Aswan University
1 shared publication
Latest Publications
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-13
Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression
Ischemic stroke is characterized by brain tissue iron accumulation. Alpha-synuclein (α-Syn) is a neuronal protein, its overexpression in ischemic stroke triggers apoptosis. Lymphocyte activation gene-3 (LAG-3), a receptor for α-Syn, enhances its neurotoxic effects. It is split from the cell membrane forming soluble LAG-3 (sLAG-3) in the bloodstream. The expression of LAG-3 in the brain, its relation to iron and α-Syn, as well as the association between serum sLAG-3 levels, iron, α-Syn, and stroke severity remains poorly understood. A case-control study was generated involving 24 patients with acute ischemic stroke and 24 healthy controls. In addition, an experimental study was designed involving 24 Wistar-albino rats. We randomly assigned rats to three groups: sham-operated, brain ischemia, and deferoxamine-treated ischemic rats. Ischemia decreased serum levels of iron, while increased serum levels of α-Syn and sLAG-3. Significant diagnostic performance of serum α-Syn and sLAG-3 was determined using the ROC curve (AUC = 0.962, 83.33% sensitivity, and 95.83% specificity for α-Syn; AUC = 0.755 with 62.50% sensitivity and 87.50% specificity for LAG-3). In rats, ischemia elevated brain tissue iron, α-Syn, and LAG-3 which were reduced following deferoxamine treatment. In conclusion, brain ischemia is associated with iron accumulation that promotes α-Syn expression and aggregation, potentially through increasing LAG-3 expression which improved after deferoxamine injection. In addition, this study illuminates the future beneficial targeting of LAG-3 in brain ischemia.
- 1 January 2026
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 104, 1-13
Deferoxamine alleviates brain ischemia/reperfusion injury through decreasing LAG-3 and α-Syn expression
Ischemic stroke is characterized by brain tissue iron accumulation. Alpha-synuclein (α-Syn) is a neuronal protein, its overexpression in ischemic stroke triggers apoptosis. Lymphocyte activation gene-3 (LAG-3), a receptor for α-Syn, enhances its neurotoxic effects. It is split from the cell membrane forming soluble LAG-3 (sLAG-3) in the bloodstream. The expression of LAG-3 in the brain, its relation to iron and α-Syn, as well as the association between serum sLAG-3 levels, iron, α-Syn, and stroke severity remains poorly understood. A case-control study was generated involving 24 patients with acute ischemic stroke and 24 healthy controls. In addition, an experimental study was designed involving 24 Wistar-albino rats. We randomly assigned rats to three groups: sham-operated, brain ischemia, and deferoxamine-treated ischemic rats. Ischemia decreased serum levels of iron, while increased serum levels of α-Syn and sLAG-3. Significant diagnostic performance of serum α-Syn and sLAG-3 was determined using the ROC curve (AUC = 0.962, 83.33% sensitivity, and 95.83% specificity for α-Syn; AUC = 0.755 with 62.50% sensitivity and 87.50% specificity for LAG-3). In rats, ischemia elevated brain tissue iron, α-Syn, and LAG-3 which were reduced following deferoxamine treatment. In conclusion, brain ischemia is associated with iron accumulation that promotes α-Syn expression and aggregation, potentially through increasing LAG-3 expression which improved after deferoxamine injection. In addition, this study illuminates the future beneficial targeting of LAG-3 in brain ischemia.
- Open Access
- 30 April 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-7
Neurofilament Light Chain Correlates with Stroke Severity and Clinical Outcome in Acute Cerebrovascular Stroke Patients
Serum neurofilament light chain (sNfL) is a marker of injury in many chronic neurological Disorders. We assessed NF-L in patients with acute stroke (ischemic or hemorrhagic) and healthy controls and clarified its association with the stroke severity, etiology, and functional outcome. This case–control study was conducted on 85 patients with first-ever acute stroke (ischemic or hemorrhagic) and 85 control subjects. Participants were subjected to through neurological history and examination. Brain imaging was performed after hospital admission. Blood tests were drawn for assessment of serum neurofilament (sNfL) levels at the first day of admission. Compared to healthy controls, our stroke patients either Ischemic or hemorrhagic had increased sNfL levels. Despite not being statistically different, ischemic stroke patients had greater levels than hemorrhagic stroke patients. Higher sNfL levels were associated with higher NIHSS scores and mRS at admission. In patients with ICH, a correlation was observed between sNfL and hematoma volume, hemorrhage location, ventricular extension and mRS. Moreover, an association of sNfL with Ischemic stroke due to large artery atherosclerosis was reported. In the absence of additional predictive variables like age and sex, it may be possible to quantify sNfL in acute plasma samples as a potential indicator of functional prognosis in patients with ischemic and hemorrhagic strokes. To validate sNfL as a biomarker for acute stroke, however, further research involving a larger number of patients is necessary.
- 30 April 2025
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 45 (1) , 1-7
Open AccessNeurofilament Light Chain Correlates with Stroke Severity and Clinical Outcome in Acute Cerebrovascular Stroke Patients
Serum neurofilament light chain (sNfL) is a marker of injury in many chronic neurological Disorders. We assessed NF-L in patients with acute stroke (ischemic or hemorrhagic) and healthy controls and clarified its association with the stroke severity, etiology, and functional outcome. This case–control study was conducted on 85 patients with first-ever acute stroke (ischemic or hemorrhagic) and 85 control subjects. Participants were subjected to through neurological history and examination. Brain imaging was performed after hospital admission. Blood tests were drawn for assessment of serum neurofilament (sNfL) levels at the first day of admission. Compared to healthy controls, our stroke patients either Ischemic or hemorrhagic had increased sNfL levels. Despite not being statistically different, ischemic stroke patients had greater levels than hemorrhagic stroke patients. Higher sNfL levels were associated with higher NIHSS scores and mRS at admission. In patients with ICH, a correlation was observed between sNfL and hematoma volume, hemorrhage location, ventricular extension and mRS. Moreover, an association of sNfL with Ischemic stroke due to large artery atherosclerosis was reported. In the absence of additional predictive variables like age and sex, it may be possible to quantify sNfL in acute plasma samples as a potential indicator of functional prognosis in patients with ischemic and hemorrhagic strokes. To validate sNfL as a biomarker for acute stroke, however, further research involving a larger number of patients is necessary.
- Open Access
- 1 October 2019
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 77 (3) , 5128-5131
Endovascular Treatment of Un-Ruptured Cerebral Aneurysms (Experience by Neurologist)
Saccular intracranial aneurysms are localized enlargement lesions of the vasculature, most commonly sited at bifurcation points in the circle of Willis. Un-ruptured intracranial aneurysms (UIA) are a common finding, occurring in about 2% of the population, making them very probable to be seen by most practitioners, and present a challenge in the recommendations for optimum management and screening. Most aneurysms do not rupture and patients harboring these lesions often remain asymptomatic. Material and Methods: we recruited 12 patients with un-ruptured intracranial aneurysms that was treated by endovascular intervention and evaluated clinically and angiographically before procedure and 3-6 months after procedure Results: the mean age of the patients was 51.42±11.23 ranging age 23 – 69 years. 6 were females and 6 were males. 5 patients (41.7 %) were hypertensive which was the commonest risk factor in those patients, 6 patients (50%) had ICA (Internal Carotid Artery) aneurysm. Conclusion: endovascular therapy of intracranial aneurysms is a safe and effective method of therapy with less morbidity and mortality rates.
- 1 October 2019
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 77 (3) , 5128-5131
Open AccessEndovascular Treatment of Un-Ruptured Cerebral Aneurysms (Experience by Neurologist)
Saccular intracranial aneurysms are localized enlargement lesions of the vasculature, most commonly sited at bifurcation points in the circle of Willis. Un-ruptured intracranial aneurysms (UIA) are a common finding, occurring in about 2% of the population, making them very probable to be seen by most practitioners, and present a challenge in the recommendations for optimum management and screening. Most aneurysms do not rupture and patients harboring these lesions often remain asymptomatic. Material and Methods: we recruited 12 patients with un-ruptured intracranial aneurysms that was treated by endovascular intervention and evaluated clinically and angiographically before procedure and 3-6 months after procedure Results: the mean age of the patients was 51.42±11.23 ranging age 23 – 69 years. 6 were females and 6 were males. 5 patients (41.7 %) were hypertensive which was the commonest risk factor in those patients, 6 patients (50%) had ICA (Internal Carotid Artery) aneurysm. Conclusion: endovascular therapy of intracranial aneurysms is a safe and effective method of therapy with less morbidity and mortality rates.
- Open Access
- 1 October 2019
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 77 (2) , 5056-5059
Endovascular Treatment of Cerebral Aneurysms Not Presented by Classic Subarachnoid Hemorrhage (First Year Experience by Neurologist)
Saccular intracranial aneurysms are localized enlargement lesions of the vasculature, most commonly sited at bifurcation points in the circle of Willis. Often they will stay asymptomatic during the life. Its common presentation is rupture that leads to subarachnoid hemorrhage (SAH) but had other presentation as ischemic stroke or compressive symptoms. Material and Methods: we recruited 16 patients with intracranial aneurysm that had presentations other than subarachnoid hemorrhage and was treated by endovascular intervention and evaluated clinically and angiographically before procedure and 3-6 months after procedure Results: the mean age of patients was 5.75±11.1 ranging between 23 – 69 years. 10 patients were females and 6 were males. 7 patients (43.8 %) were hypertensive which was the commonest risk factor in those patients. 6 patients (37.5%) had ICA aneurysm. Conclusion: endovascular therapy of intracranial aneurysms is a safe and effective method of therapy with less morbidity and mortality rates.
- 1 October 2019
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 77 (2) , 5056-5059
Open AccessEndovascular Treatment of Cerebral Aneurysms Not Presented by Classic Subarachnoid Hemorrhage (First Year Experience by Neurologist)
Saccular intracranial aneurysms are localized enlargement lesions of the vasculature, most commonly sited at bifurcation points in the circle of Willis. Often they will stay asymptomatic during the life. Its common presentation is rupture that leads to subarachnoid hemorrhage (SAH) but had other presentation as ischemic stroke or compressive symptoms. Material and Methods: we recruited 16 patients with intracranial aneurysm that had presentations other than subarachnoid hemorrhage and was treated by endovascular intervention and evaluated clinically and angiographically before procedure and 3-6 months after procedure Results: the mean age of patients was 5.75±11.1 ranging between 23 – 69 years. 10 patients were females and 6 were males. 7 patients (43.8 %) were hypertensive which was the commonest risk factor in those patients. 6 patients (37.5%) had ICA aneurysm. Conclusion: endovascular therapy of intracranial aneurysms is a safe and effective method of therapy with less morbidity and mortality rates.